Explore Taconic's portfolio of Parkinson's disease models and learn how our strategic partnership with the Michael J. Fox Foundation drives groundbreaking research. Discover the advanced tools and resources available to accelerate your Parkinson's disease studies.
The loss of nigrostriatal dopamine neurons and reduced motor abilities are consequences of Parkinson's Disease. Mutations in the LRRK2 and alpha synuclein (SNCA) genes are associated with familial Parkinson's disease and affect the nigrostriatal pathway.
The rat as an experimental organism can offer some unique strengths compared to mice:
The aSyn SNCA Knockout Rat (Model 22966) is a valuable model for Parkinson’s Disease (PD) research. Originally generated at SAGE Labs and now available through Taconic as of April 2025, this model uses CRISPR/Cas9 to delete the endogenous SNCA gene and enables targeted study of alpha-synuclein’s role in neurodegeneration.
The aSyn A53T SNCA Knock-In Rat (Model 22964) supports Parkinson’s Disease (PD) research by replicating a key human SNCA mutation linked to both familial and sporadic forms of the disease. Created using CRISPR/Cas9 and first available through Taconic in April 2025, the aSyn A53T SNCA Knock-In Rat expresses a humanized A53T-mutated alpha-synuclein protein, with the endogenous rat SNCA gene rendered nonfunctional.
Model 21546 is a conditional knock-out of the PRKN gene.
*Discontinued. Please contact Taconic if you need this line.
Model 16552 is a constitutive knock-in of murine Rab29 under control of the Pgk promoter generated by targeted transgenesis into the ROSA26 locus.
Model 13940 has the human G2019S point mutation introduced into exon 41 of the mouse LRRK2 gene. Additionally, exon 41 is flanked by lox P sites, potentially allowing generation of a LRRK2 gene constitutive KO model upon intercrossing with a Cre-deleter strain. See model page for more information.
What our customers say:
“Robust, well-validated pre-clinical models of Parkinson's disease are a necessary tool for understanding the biology and possible treatment of this complex disease. With dedicated project management and technical support, Taconic has been a reliable partner in The Michael J. Fox Foundation's efforts to provide the research community with important, field-enabling pre-clinical models. We look forward to continuing to partner with Taconic for custom model generation projects.”
The Michael J. Fox Foundation